Gary M. Owens Sells 1,939 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) CEO Gary M. Owens sold 1,939 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $97.12, for a total transaction of $188,315.68. Following the transaction, the chief executive officer now owns 45,824 shares in the company, valued at approximately $4,450,426.88. This represents a 4.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Mesa Laboratories Stock Up 2.1%

Shares of NASDAQ:MLAB traded up $1.97 during trading on Wednesday, reaching $94.70. The stock had a trading volume of 164,868 shares, compared to its average volume of 53,589. Mesa Laboratories, Inc. has a one year low of $83.68 and a one year high of $155.12. The company has a market capitalization of $517.04 million, a P/E ratio of -255.83 and a beta of 0.88. The company has a current ratio of 0.63, a quick ratio of 0.47 and a debt-to-equity ratio of 0.48. The firm's 50-day simple moving average is $111.75 and its 200 day simple moving average is $125.47.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 16th. Investors of record on Friday, May 30th were given a dividend of $0.16 per share. The ex-dividend date was Friday, May 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.68%. Mesa Laboratories's payout ratio is -172.97%.

Institutional Investors Weigh In On Mesa Laboratories

Institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Mesa Laboratories by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,925 shares of the medical instruments supplier's stock valued at $386,000 after acquiring an additional 98 shares in the last quarter. Los Angeles Capital Management LLC grew its position in Mesa Laboratories by 3.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier's stock worth $448,000 after purchasing an additional 100 shares during the last quarter. Alliancebernstein L.P. increased its stake in Mesa Laboratories by 2.6% during the 4th quarter. Alliancebernstein L.P. now owns 5,584 shares of the medical instruments supplier's stock valued at $736,000 after purchasing an additional 141 shares in the last quarter. Amundi increased its stake in Mesa Laboratories by 81.6% during the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock valued at $91,000 after purchasing an additional 297 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Mesa Laboratories by 1.2% in the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier's stock worth $3,652,000 after buying an additional 353 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wall Street Zen lowered Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a report on Friday, May 30th. Wells Fargo & Company decreased their price objective on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a research note on Friday, May 30th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.